Recent Articles
Clover Health Desperately Needs Triage, but It Isn’t Doomed Yet
By
Nicolas Chahine, InvestorPlace Contributor
Clover Health has a billion dollar yearly book of sales. Selloffs have limits, and we will soon find out if CLOV stock is a dud or a stud.
3 Biotech Stocks to Buy That Are Under Severe Pressure
By
Nicolas Chahine, InvestorPlace Contributor
The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom.
The Cloudflare Stock Dip Is an Enticing Buying Opportunity
By
Nicolas Chahine, InvestorPlace Contributor
Cloudflare positioned itself well for the long term. So NET stock 50% correction is an opportunity for new investors but not all in.
With Political Volatility, $140 Will Be a Key Point for Alibaba Stock
By
Nicolas Chahine, InvestorPlace Contributor
BABA stock is inherently pretty risky, but there's reason to believe it could grow from here. $140 will be a crucial point in its ascent.
A Bounce Back From Its Lows Makes AT&T an Appealing Dividend Stock
By
Nicolas Chahine, InvestorPlace Contributor
T stock has reached a stage in its chart that can best be described as "so bad it's good." It's a good time to enter a position with AT&T.
Join Louis Navellier’s Market 360 — FREE!
Get Louis Navellier’s take on the news and events impacting the market, plus his top stock picks.
